Telehealth Unit Economics: CAC, LTV & Margins When You Own Your Stack

A telehealth clinic's unit economics turn on four numbers: customer acquisition cost (CAC), gross margin on the compounded prescription, refill retention, and payback period. CAC ranges from roughly $70–300 in men's health to $150–600 in women's health (directional estimates). Gross margin on compounded Rx runs 55–75% before platform and provider costs. Owning your patient data and order system of record — instead of leasing them from an all-in-one platform — can recover 8–15 percentage points of margin lost to revenue share and reactivation lock-in.

---

If you have spent any time on the unit economics of a DTC prescription business, you have probably run the math three or four times and gotten a different answer each time. That is not a coincidence. The model looks clean on the surface — recurring revenue, high gross margin, subscription retention — and then you actually itemize the cost stack and realize the number you were missing is buried in your platform contract.

This page is a plainspoken P&L walkthrough. All numbers are directional estimates drawn from operator-reported ranges unless otherwise noted. The goal is to give you a working model, show you where the leaks are, and be honest about what changes when you own the patient relationship versus renting it from a platform.

Nothing here is legal or financial advice. Provider approval is a non-negotiable in every scenario discussed — nothing ships without a licensed provider signing off on every order.

---

What Does a Healthy Telehealth P&L Actually Look Like?

Before drilling into individual line items, here is a representative composite for a subscription-based compounded Rx clinic at 100–500 active patients (all figures estimated unless cited):

Line item	Range (per patient/month)
Monthly subscription or Rx revenue	$80 – $250
Compounded Rx + dispensing fee	$25 – $80
Shipping	$8 – $20
Provider / clinician cost	$10 – $30
Platform fee or revenue share	$10 – $40
Payment processing	$3 – $8
Gross profit (before CAC amortization)	$20 – $110

The swing between the low and high ends of that gross profit range is not about category — it is almost entirely about cost-stack control. Specifically: whether you are paying a revenue share to an all-in-one platform or paying a fixed infrastructure fee on a stack you own.

---

What Are Realistic CAC Ranges by Category?

Men's Health (TRT, ED, Hair)

CAC in men's health is the most widely cited benchmark in the space because the category has been running paid acquisition longest. Directional estimates from operator conversations and public commentary:

• Organic / SEO / referral CAC: $30 – $100
• Paid social (Meta, TikTok): $70 – $180
• Blended (paid + organic at scale): $100 – $300

Men's health has the tightest CAC range because the category is mature, purchase intent is clear, and the conversion funnel from quiz to checkout is well understood. The downside is competitive saturation. CAC is rising as incumbents spend heavily.

Women's Health (HRT, Menopause, Fertility)

CAC here is meaningfully higher because the awareness and education layer is longer. Women researching HRT or menopause protocols spend more time evaluating before converting. Directional estimates:

• Paid social + content: $150 – $400
• Blended at maturity: $200 – $600

The offset is that HRT and menopause patients tend to carry significantly higher LTV — refill retention is strong when the protocol is working and the provider relationship is solid.

Aesthetics and Skin (Tretinoin, Custom Topicals)

Skin is increasingly a D2C commodity with aggressive CAC from well-funded competitors (Curology, Apostrophe, Hims/Hers skin lines). New entrants face:

• Blended CAC: $80 – $250
• Key insight: margins compress unless you own the pharmacy relationship and can negotiate dispensing cost directly. A platform that routes to its own compounding partner is skimming the dispensing margin you should keep.

Functional / Integrative (LDN, Peptides, Custom Compounds)

This is the most operator-favorable category on unit economics right now. Search demand for peptides and longevity protocols is growing fast (US monthly search volume for peptide-related terms is estimated to have surpassed major weight-loss drug branded terms). CAC is lower because you are not competing with nine-figure ad budgets:

• Content + community CAC: $40 – $120
• Paid CAC: $100 – $250

The risk is regulatory flux around specific peptides. Diversification across formulations and a pharmacy partner who can adapt is more important than margin optimization in this category.

What Moves CAC More Than Anything Else

The single biggest CAC lever for a bootstrapped operator is owning the patient record and being able to run win-back and reactivation workflows on your own database. If you are on a platform and a patient lapses, their contact information and order history may be inside the platform's walls. Your reactivation email goes through the platform's tooling, on the platform's terms, or not at all. That is not a feature gap — that is structural CAC inflation. Every lapsed patient you cannot directly reactivate becomes a patient you re-acquire at full cost.

---

How Does Gross Margin on Compounded Rx Actually Stack Up?

Gross margin on a compounded prescription at a 503A or 503B pharmacy runs meaningfully higher than a branded pharmaceutical fill. Here is why and what the numbers look like.

Compounded Rx Margin Structure (Estimated)

Component	Typical range
Patient-facing price (monthly Rx/protocol)	$80 – $250
Pharmacy ingredient + compounding fee	$15 – $55
Dispensing + packaging	$5 – $20
Gross margin before shipping + provider	55% – 75%

The key word is "before." The 55–75% figure is the gross on the pharmacy transaction. It does not yet include:

• Shipping ($8–20/shipment, cold chain higher)
• Provider / prescriber cost ($10–30/patient/month depending on model)
• Platform fee or infrastructure cost

After those three line items, net contribution margin per patient per month typically lands in the $20–80 range on a $120–200 subscription. That is the number you actually compound over the life of a patient relationship.

A note on compounded vs. FDA-approved: Compounded medications are produced by licensed 503A or 503B pharmacies. They are not FDA-approved. Provider approval is mandatory on every order — a licensed clinician must review and authorize before anything ships. This is not an optional compliance layer. It is a load-bearing part of the business model and every operator should publish it clearly.

Where Platform Revenue Share Destroys Gross Margin

A typical all-in-one telehealth platform charges one or more of the following:

1. A percentage of GMV (commonly 10–20%)
2. A per-order fee
3. A dispensing margin built into the pharmacy they route to (opaque, but real)

On a $150/month subscription, a 15% revenue share is $22.50 per patient per month — coming directly off your gross margin. At 300 patients, that is $6,750/month — $81,000/year — flowing to the platform, not your business.

That number is not hypothetical. It is the difference between a viable clinic and one that is perpetually raising or burning.

---

What Does LTV Look Like and What Actually Drives Retention?

LTV Model (Composite Estimate)

For a subscription compounded Rx clinic, LTV depends almost entirely on two variables: average monthly contribution margin and monthly churn rate.

Monthly churn rate	12-month LTV (at $50 net contribution/month)	24-month LTV
5% (strong retention)	~$490	~$760
8% (moderate)	~$415	~$600
12% (high)	~$330	~$440
15% (weak)	~$285	~$360

All figures estimated. LTV = (monthly net contribution) / (monthly churn rate).

The practical implication: a clinic that gets churn from 12% to 8% per month increases LTV by roughly 36% without touching CAC. That is almost always a higher-return intervention than spending more on acquisition.

What Actually Drives Churn in Compounded Rx Clinics

1. Protocol not working / wrong formulation: the provider relationship and formulary flexibility matter more than most operators acknowledge. If you are locked to one pharmacy's catalog, you cannot adjust compounding parameters without switching pharmacies — which may not be possible on an all-in-one platform.
2. Shipping and fulfillment failures: cold-chain failures, delays, tracking lapses. These are attribution-blind to most platforms. If you own the order record, you can see exactly where the failure happened. If you do not, you know only that the patient churned.
3. Inability to reactivate lapsed patients: see above. Reactivation is the cheapest LTV extension available, and it only works if you own the contact and order history.
4. Price sensitivity at refill: a patient who signed up on a promo, converted to full price at month two, and lapsed at month three never had the LTV the model promised.

Payback Period

At a blended CAC of $150 and a net contribution of $50/month, payback is three months. At $300 CAC, payback is six months. The math is simple, but the constraint is cash: a clinic scaling aggressively at $300 CAC and six-month payback needs to carry six months of patient acquisition cost before the first dollar of contribution returns. That is a working capital problem most bootstrapped operators underestimate.

Payback shortens materially when you can charge a higher first-order price (intake consultation, lab panel, or protocol setup fee) — common in functional medicine and longevity — or when your refill retention is high enough to reduce effective per-period churn.

---

How Does Owning Your Stack Actually Change the Math?

This is the core question. The argument for owning your stack is not ideological — it is economic. Here is where the math changes:

1. Revenue Share vs. Infrastructure Cost

A platform charging 15% revenue share on $200/month from 200 patients takes $6,000/month. A fixed infrastructure rail might cost $500–2,000/month regardless of patient volume. The crossover happens somewhere between 30 and 80 patients depending on the specific contract terms. Above that threshold, the owned-infrastructure model is strictly cheaper per patient — and the gap widens with scale.

2. Reactivation and Win-Back Economics

When you own the patient record, a six-month lapsed patient costs you one email sequence to potentially reactivate. No re-acquisition ad spend. No lead fee. Just your time and your email list. Operators running their own CRM report meaningful reactivation rates (some as high as 20–30% on 90-day lapse segments with targeted win-back copy). That is a free LTV extension that a platform cannot give you because the platform's incentive is that you re-acquire through their funnel.

3. Formulary and Pharmacy Flexibility

A clinic that is not locked to one pharmacy's catalog can negotiate on dispensing cost, switch to a secondary compounder when supply is constrained, and add new formulations as clinical evidence or demand develops. In a category where regulatory positions on specific molecules shift year over year, formulary flexibility is a business continuity tool, not just a margin lever.

The July 2026 FDA 503B compounding decision on specific weight-loss drug molecules is a live example. Clinics that built their entire book on one molecule and one pharmacy are facing a cliff. Clinics on a flexible rail with multi-pharmacy routing and a diversified formulary — TRT, HRT, hair, ED, tretinoin, LDN, peptides, oral metabolic, custom compounds — have options. That is not about GLP-1 specifically. It is about what a monoculture book does to your unit economics when the rules change.

4. Data-Driven CAC Optimization

Owning the full order history — which SKUs convert, which refill, which churn after the second fill — is a targeting asset for your paid channels. If your patient data lives in a platform's database, you cannot build custom audiences from it, cannot model LTV by acquisition source, and cannot make an informed bid on the next patient. The operators who know their LTV-by-channel to three decimal places are invariably the ones who own their data.

Ownership vs. Rented Stack: Economic Summary (Estimated, Composite)

Metric	All-in-one platform	Own your stack (neolife rail)
Revenue share / platform fee (200 patients, $180 avg)	~$5,400/mo (15% GMV)	~$800–1,500/mo (fixed infra)
Reactivation cost per lapsed patient	$80–150 (re-acquisition)	$0–5 (email to owned list)
Pharmacy margin control	Platform routes, margin opaque	Direct relationship, negotiable
LTV visibility by channel	Limited / requires export	Full, native
Formulary flexibility	Platform catalog	Multi-pharmacy, operator-defined
Estimated annual margin difference at 200 patients	Baseline	+$45,000–$60,000 (estimated)

Figures are composite estimates for illustration. Your actual numbers will vary by category, volume, and contract terms.

---

What Is the Right Order of Optimization?

If you are earlier stage, the priority stack looks like this:

Step 1 — Fix churn before scaling acquisition. At sub-5% monthly churn, scaling acquisition has a compounding effect. Above 10%, every dollar you spend on acquisition is fighting attrition. Diagnose churn causes first (formulation, shipping, price) before spending more on top-of-funnel.

Step 2 — Get off per-order or GMV-based pricing as early as possible. The longer you stay on a percentage-of-GMV structure, the harder it is to model your business. Fixed infrastructure cost is the right structure the moment you can negotiate it.

Step 3 — Own your patient data and order history now, not later. Migrating patient data out of a platform is painful. Export formats are inconsistent. The longer you wait, the more patients you have, and the more painful the transition becomes. Build on a stack where you are the system of record from the first order.

Step 4 — Diversify your formulary early. A multi-formulation book is not just a regulatory hedge — it is a conversion tool (patients who do not convert on one protocol often convert on another) and a retention tool (patients who plateau on one protocol can transition to a complementary one).

Step 5 — Then scale acquisition. With churn controlled, margin structure fixed, patient data owned, and formulary diversified, CAC spend has a predictable return profile. This is when paid channels make sense.

---

The Compounding Effect of Ownership

Here is the long version of the argument made short.

A 200-patient clinic on an all-in-one platform at $180/month average revenue, 15% revenue share, and 10% monthly churn generates roughly:

• Monthly GMV: $36,000
• Platform take: $5,400
• Monthly churn patient count: ~20 patients
• Monthly re-acquisition cost at $200 CAC: $4,000
• Combined platform + reacquisition drag: ~$9,400/month

The same clinic on owned infrastructure — fixed rail cost of $1,200/month, reactivation email cost near zero, 8% churn from better formulary management:

• Monthly infra cost: $1,200
• Monthly churn patient count: ~16 patients
• Monthly reactivation cost (email win-back, 25% recovery): ~$600 effective re-acquisition spend
• Combined infra + reactivation drag: ~$1,800/month

The difference — roughly $7,600/month, or $91,000/year on 200 patients — is not from a better product. It is from a different ownership structure. At 500 patients, that number roughly doubles.

That is what owning your stack is actually worth. Not freedom in the abstract. Ninety thousand dollars a year that compounds as you grow.

---

Key Takeaways

• CAC varies widely by category — men's health blended $100–300 (estimated), women's health $200–600 (estimated), functional medicine $40–250 — but reactivation cost is always near zero if you own the patient record.
• Gross margin on compounded Rx runs 55–75% before shipping, provider cost, and platform fees. After those, net contribution per patient is typically $20–80/month.
• Payback period is 3–6 months at typical CAC and contribution margin ranges. The cash requirement to fund that payback period is the most underestimated constraint in scaling.
• Monthly churn is the biggest LTV lever. Moving churn from 12% to 8% increases LTV by roughly 36% without touching acquisition.
• Revenue share structures are CAC-equivalent costs. A 15% GMV take on 200 patients is $5,000+/month — money that should compound inside your business.
• Formulary diversification is a unit-economics tool, not just regulatory compliance. A multi-formulation, multi-pharmacy book has lower category-risk-adjusted churn.
• Owning patient data and order history changes CAC math, reactivation economics, and LTV modeling. These are not soft benefits. They show up in the P&L.
• A licensed provider approves every order in a well-run clinic. That is not a cost to minimize — it is the compliance foundation that keeps the business alive long enough to compound.

---

FAQ

What is a realistic payback period for a telehealth clinic? At a blended CAC of $150 and $50/month net contribution per patient, payback is three months. At $300 CAC, six months. Payback shortens if you charge a meaningful intake or protocol setup fee at first order, which is common in functional medicine and longevity programs. Above $500 CAC with sub-$50 monthly contribution, the model requires significant volume and low churn to work.

How does a telehealth platform's revenue share affect unit economics? A 15% GMV revenue share on a $150/month subscription is $22.50 per patient per month. At 200 patients, that is $4,500/month — more than $50,000/year — coming off your gross margin before you account for any other operating cost. The share compounds as you grow, which is why the crossover to fixed infrastructure cost typically happens somewhere between 30 and 80 patients.

What is a healthy churn rate for a compounded Rx subscription clinic? Monthly churn below 5% is strong. 8% is workable if your CAC is low and reactivation is active. Above 12%, you are likely running on a treadmill — acquiring patients at the same rate you are losing them. Churn diagnostics (shipping failures, formulary mismatch, price shock at refill) should precede any scale in acquisition spend.

Does owning patient data actually change CAC? Not on first acquisition — your first-order CAC is the same regardless of what stack you run. But effective CAC over time drops when you can reactivate lapsed patients directly (email, SMS) rather than re-acquiring them through paid channels. Operators with owned lists and full order history report effective long-run CAC meaningfully below their first-order paid CAC.

What is the right gross margin target for a compounded Rx telehealth clinic? Directionally, you want 55–70% gross margin on the prescription transaction before shipping and provider costs. After those, a net contribution margin in the 30–45% range (as a percentage of patient revenue) is healthy at scale. Below 25% net contribution, the CAC payback math becomes very sensitive to churn, and any revenue-share cost eats the model.

How does formulary diversification affect unit economics? A patient who does not convert on one formulation often converts on a related one. Multi-protocol clinics report lower overall churn because patients who plateau or experience side effects on one protocol can transition rather than cancel. The economics compound: lower churn raises LTV, lower LTV sensitivity to CAC means you can afford more disciplined paid acquisition, and a diversified book is less exposed to single-molecule regulatory shifts.

---

Related reading: Own Your Telehealth Stack: Escaping Platform Lock-In · How to Launch a Telehealth Business in 2026 · Compounding Pharmacy Fulfillment for Telehealth · 503A vs. 503B: The Operator's Guide to Compounding Pharmacy Tiers · Telehealth Compliance for Operators: LegitScript, HIPAA & Provider Oversight · TRT Clinic Launch Playbook · Beyond GLP-1: Building a Durable Metabolic Formulary

---

neolife is the fulfillment rail that connects your Shopify store to your pharmacy — orders out in under 60 seconds, a licensed provider approves every one, and your clinic stays the system of record. If you want to run the unit economics on your own numbers, get in touch.